

# Alexander Eggermont

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1176954/publications.pdf>

Version: 2024-02-01

8  
papers

7,214  
citations

1307594

7  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

9654  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a core outcome set for basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 573-581.	1.2	5
2	Harnessing the microbiome to restore immunotherapy response. <i>Nature Cancer</i> , 2021, 2, 1301-1304.	13.2	10
3	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	12.6	217
4	PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. <i>British Journal of Cancer</i> , 2019, 120, 3-5.	6.4	87
5	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
6	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , 2017, 8, 108786-108801.	1.8	22
7	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.	14.3	645
8	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	12.6	2,539